A soon-to-be-published analysis comparing Roche's cancer medicine Avastin and Novartis's eye drug Lucentis in treating an eye disease could fan health concerns over Avastin's off-label use and thus avert a feared slide in Lucentis sales in the U.S.
WSJ.com: What's News US, Wall Street Journal
Mon, 04/04/2011 - 2:47am
A soon-to-be-published analysis comparing Roche's cancer medicine Avastin and Novartis's eye drug Lucentis in treating an eye disease could fan health concerns over Avastin's off-label use and thus avert a feared slide in Lucentis sales in the U.S.